These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 25517711)

  • 1. Glucocorticoids and mepolizumab in eosinophilic asthma.
    Bel EH; Ortega HG; Pavord ID
    N Engl J Med; 2014 Dec; 371(25):2434. PubMed ID: 25517711
    [No Abstract]   [Full Text] [Related]  

  • 2. Glucocorticoids and mepolizumab in eosinophilic asthma.
    Iikura M; Hojo M; Sugiyama H
    N Engl J Med; 2014 Dec; 371(25):2433-4. PubMed ID: 25517713
    [No Abstract]   [Full Text] [Related]  

  • 3. Glucocorticoids and mepolizumab in eosinophilic asthma.
    Lindsay JT; Heaney L
    N Engl J Med; 2014 Dec; 371(25):2433. PubMed ID: 25517712
    [No Abstract]   [Full Text] [Related]  

  • 4. [Asthma: how does mepolizumab affect exacerbations and need for steroids? Mepolizumab is a new therapeutic option in severe asthma [corrected]].
    Taube C
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2380. PubMed ID: 25390624
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-interleukin-5 monoclonal antibody to treat severe eosinophilic asthma.
    Nair P
    N Engl J Med; 2014 Sep; 371(13):1249-51. PubMed ID: 25197762
    [No Abstract]   [Full Text] [Related]  

  • 6. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
    Bel EH; Wenzel SE; Thompson PJ; Prazma CM; Keene ON; Yancey SW; Ortega HG; Pavord ID;
    N Engl J Med; 2014 Sep; 371(13):1189-97. PubMed ID: 25199060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study.
    Lugogo N; Domingo C; Chanez P; Leigh R; Gilson MJ; Price RG; Yancey SW; Ortega HG
    Clin Ther; 2016 Sep; 38(9):2058-2070.e1. PubMed ID: 27553751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic drug evaluation of mepolizumab for the treatment of severe asthma associated with persistent eosinophilic inflammation in adults.
    Kallur L; Gonzalez-Estrada A; Eidelman F; Dimov V
    Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1275-1280. PubMed ID: 29157020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mepolizumab: First Global Approval.
    Keating GM
    Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study.
    Pelaia C; Busceti MT; Solinas S; Terracciano R; Pelaia G
    Pulm Pharmacol Ther; 2018 Dec; 53():1-5. PubMed ID: 30217438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mepolizumab (Nucala) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2016 Jan; 58(1486):11-2. PubMed ID: 26761344
    [No Abstract]   [Full Text] [Related]  

  • 12. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
    Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
    Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benralizumab (Fasenra) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2018 Feb; 60(1541):33-35. PubMed ID: 29485975
    [No Abstract]   [Full Text] [Related]  

  • 14. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype.
    Basu A; Dalal A; Canonica GW; Forshag M; Yancey SW; Nagar S; Bell CF
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):121-131. PubMed ID: 28277854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma.
    Shimoda T; Odajima H; Okamasa A; Kawase M; Komatsubara M; Mayer B; Yancey S; Ortega H
    Allergol Int; 2017 Jul; 66(3):445-451. PubMed ID: 28110896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
    Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
    Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. May mepolizumab used in asthma correct subfertility?
    Ozden G; Pınar Deniz P
    Ann Med; 2021 Dec; 53(1):456-458. PubMed ID: 33739210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reslizumab (Cinqair) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2016 Jun; 58(1497):81-2. PubMed ID: 27305070
    [No Abstract]   [Full Text] [Related]  

  • 19. Mepolizumab approved as add-on long-term therapy for severe asthma.
    Thompson CA
    Am J Health Syst Pharm; 2015 Dec; 72(24):2125. PubMed ID: 26637509
    [No Abstract]   [Full Text] [Related]  

  • 20. Exacerbations of severe asthma in patients treated with mepolizumab.
    Shrimanker R; Pavord ID; Yancey S; Heaney LG; Green RH; Bradding P; Hargadon B; Brightling CE; Wardlaw AJ; Haldar P
    Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30464012
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.